Fundraising FoxCombinati Incorporated
Palo Alto, US · Founded 2015 · 4 known investors
Find your way into Combinati Incorporated
Sign up to see every warm intro you have to Combinati Incorporated
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Combinati Incorporated team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Combinati developed the QuantStudio Absolute Q Digital PCR System, which uses microfluidic array plate (MAP) technology for detection and quantification of nucleic acids, rare mutations, and genome editing events. The platform serves research laboratories for applications such as next-generation sequencing library quantification and CRISPR-Cas9 editing analysis.
Founders & leadership
Investors · 4
How we know: Band of Angels's portfolio page · Not right? Tell us
How we know: BayMed Venture Partners's portfolio page · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$5.8M disclosed across 1 round · 2018
▶$5.8MraisedMay 2018 · 34 investors · BiotechnologyRule 506(b)
- Michael MokelkeDirector
- Ju-Sung (Paul) HungExecutive Officer, Director
- Charles CollinsDirector
- Offering amount
- $5.8M
- Amount sold
- $5.8M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 7 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $772.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2019 | $224.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $1.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $215K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $700K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Combinati Incorporated do?
- Combinati developed the QuantStudio Absolute Q Digital PCR System, which uses microfluidic array plate (MAP) technology for detection and quantification of nucleic acids, rare mutations, and genome editing events. The platform serves research laboratories for applications such as next-generation sequencing library quantification and CRISPR-Cas9 editing analysis.
- Who are Combinati Incorporated's investors?
- Combinati Incorporated's investors include Band of Angels, BayMed Venture Partners, Endurance28, IT-Farm Corporation.
- How much funding has Combinati Incorporated raised?
- Combinati Incorporated has disclosed $5.8M raised across 1 round.
- Where is Combinati Incorporated headquartered?
- Combinati Incorporated is headquartered in Palo Alto, US.